Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Q32 Bio (QTTB) over the last 9 years, with Q3 2025 value amounting to -$511000.0.

  • Q32 Bio's Change in Accured Expenses rose 7135.65% to -$511000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 696.71%. This contributed to the annual value of -$7.7 million for FY2024, which is 397638.19% down from last year.
  • Per Q32 Bio's latest filing, its Change in Accured Expenses stood at -$511000.0 for Q3 2025, which was up 7135.65% from -$889000.0 recorded in Q2 2025.
  • Q32 Bio's 5-year Change in Accured Expenses high stood at $6.6 million for Q2 2022, and its period low was -$5.0 million during Q1 2022.
  • Over the past 5 years, Q32 Bio's median Change in Accured Expenses value was -$889000.0 (recorded in 2025), while the average stood at -$117421.1.
  • Data for Q32 Bio's Change in Accured Expenses shows a peak YoY increase of 34180.5% (in 2021) and a maximum YoY decrease of 74859.81% (in 2021) over the last 5 years.
  • Q32 Bio's Change in Accured Expenses (Quarter) stood at $1.3 million in 2021, then soared by 36.94% to $1.7 million in 2022, then soared by 34.42% to $2.3 million in 2023, then crashed by 143.37% to -$1.0 million in 2024, then soared by 49.8% to -$511000.0 in 2025.
  • Its last three reported values are -$511000.0 in Q3 2025, -$889000.0 for Q2 2025, and -$2.2 million during Q1 2025.